Dialysis

Dialysis News

  • Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy Hope that observed renoprotective effects of SGLT2 inhibitors will delay worsening of kidney disease in type 2 diabetes seems to be borne out, as the CREDENCE trial is stopped early.
  • HCV-Positive Kidneys Cost-Effective for HCV-Positive Recipients Quality-adjusted life expectancy is greater and costs are lower when kidney transplant candidates infected with hepatitis C virus (HCV) receive HCV-positive kidneys than when they receive HCV-negative kidneys, according to a cost-effectiveness analysis.
 

Dialysis Perspective

 

Journals

 
https://www.pills24.com.ua/

viagraon.com

http://www.medicaments-24.net/